• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病的流行病学、病理学、遗传学和发病机制。

Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.

机构信息

Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue Boston, MA 02215, USA.

Department of Neurology, University of California - San Francisco, 1635 Divisadero St., Suite 520-530, San Francisco, CA 94115; Parkinson's Disease Research Education and Clinical Center San Francisco Veteran's Affairs Medical Center, 4150 Clement St. (127P), San Francisco, CA 94121.

出版信息

Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24.

DOI:10.1016/j.cger.2019.08.002
PMID:31733690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6905381/
Abstract

Parkinson disease is a complex, age-related, neurodegenerative disease associated with dopamine deficiency and both motor and nonmotor deficits. Many environmental and genetic factors influence Parkinson disease risk, with different factors predominating in different patients. These factors converge on specific pathways, including mitochondrial dysfunction, oxidative stress, protein aggregation, impaired autophagy, and neuroinflammation. Ultimately, treatment of Parkinson disease may focus on targeted therapies for pathophysiologically defined subtypes of Parkinson disease patients.

摘要

帕金森病是一种复杂的、与年龄相关的神经退行性疾病,与多巴胺缺乏以及运动和非运动缺陷有关。许多环境和遗传因素影响帕金森病的风险,不同的因素在不同的患者中占主导地位。这些因素集中在特定的途径上,包括线粒体功能障碍、氧化应激、蛋白质聚集、自噬受损和神经炎症。最终,帕金森病的治疗可能集中在针对帕金森病患者病理生理定义亚型的靶向治疗上。

相似文献

1
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology.帕金森病的流行病学、病理学、遗传学和发病机制。
Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24.
2
Parkinson disease: from pathology to molecular disease mechanisms.帕金森病:从病理学到分子疾病机制。
Free Radic Biol Med. 2013 Sep;62:132-144. doi: 10.1016/j.freeradbiomed.2013.01.018. Epub 2013 Feb 4.
3
Management of Urologic and Sexual Dysfunction in Parkinson Disease.帕金森病的泌尿系统和性功能障碍管理。
Clin Geriatr Med. 2020 Feb;36(1):69-80. doi: 10.1016/j.cger.2019.09.011. Epub 2019 Sep 10.
4
Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.重印本:重新探讨氧化应激和线粒体功能障碍在帕金森病发病机制中的作用——类似于安非他命类药物滥用的影响。
Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3.
5
Management of Motor Features in Advanced Parkinson Disease.晚期帕金森病运动症状的管理。
Clin Geriatr Med. 2020 Feb;36(1):43-52. doi: 10.1016/j.cger.2019.09.010. Epub 2019 Sep 10.
6
Epidemiology of Parkinson Disease.帕金森病的流行病学
Neurol Clin. 2016 Nov;34(4):955-965. doi: 10.1016/j.ncl.2016.06.012. Epub 2016 Aug 18.
7
Parkinson Disease.帕金森病
Clin Geriatr Med. 2020 Feb;36(1):xiii-xiv. doi: 10.1016/j.cger.2019.10.001. Epub 2019 Oct 5.
8
Gastrointestinal Care of the Parkinson Patient.帕金森病患者的胃肠道护理。
Clin Geriatr Med. 2020 Feb;36(1):81-92. doi: 10.1016/j.cger.2019.09.003. Epub 2019 Sep 6.
9
Parkinson's disease: etiopathogenesis and treatment.帕金森病:病因发病机制与治疗。
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi: 10.1136/jnnp-2019-322338. Epub 2020 Jun 23.
10
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.散发型帕金森病出现运动障碍之前的神经病理学:临床前期帕金森病。
J Neural Transm (Vienna). 2011 May;118(5):821-39. doi: 10.1007/s00702-010-0482-8. Epub 2010 Sep 23.

引用本文的文献

1
Spotlight on USP30: structure, function, disease and target inhibition.聚焦USP30:结构、功能、疾病与靶向抑制
Front Pharmacol. 2025 Aug 22;16:1629709. doi: 10.3389/fphar.2025.1629709. eCollection 2025.
2
MicroRNAs and synaptic dysfunction in Parkinson's disease.帕金森病中的微小RNA与突触功能障碍
Mol Ther Nucleic Acids. 2025 Aug 12;36(3):102673. doi: 10.1016/j.omtn.2025.102673. eCollection 2025 Sep 9.
3
Astrocyte Autophagy in Neurodegenerative Diseases: Current Progress in Mechanisms and Therapeutics.神经退行性疾病中的星形胶质细胞自噬:机制与治疗的当前进展

本文引用的文献

1
, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches.戈谢病、帕金森病:从遗传学到临床再到新的治疗方法。
Cells. 2019 Apr 19;8(4):364. doi: 10.3390/cells8040364.
2
Is Parkinson's disease a chronic low-grade inflammatory bowel disease?帕金森病是一种慢性低度炎症性肠病吗?
J Neurol. 2020 Aug;267(8):2207-2213. doi: 10.1007/s00415-019-09321-0. Epub 2019 Apr 12.
3
Entanglement of Genetics and Epigenetics in Parkinson's Disease.帕金森病中遗传学与表观遗传学的相互作用
Neurochem Res. 2025 Sep 5;50(5):287. doi: 10.1007/s11064-025-04532-6.
4
Comparative study of autonomic dysfunction between Parkinson's disease with LRRK2, PRKN, and GBA mutations.携带LRRK2、PRKN和GBA基因突变的帕金森病患者自主神经功能障碍的比较研究
Front Neurol. 2025 Aug 19;16:1657824. doi: 10.3389/fneur.2025.1657824. eCollection 2025.
5
Acupuncture for Parkinson's Disease: A Narrative Review of Clinical Efficacy and Mechanistic Insights.针灸治疗帕金森病:临床疗效与作用机制的叙述性综述
Neuropsychiatr Dis Treat. 2025 Aug 22;21:1731-1750. doi: 10.2147/NDT.S532027. eCollection 2025.
6
The Relationship Between Systemic Inflammatory Index and Other Inflammatory Markers with Clinical Severity of the Disease in Patients with Parkinson's Disease.帕金森病患者全身炎症指数及其他炎症标志物与疾病临床严重程度的关系
Biomedicines. 2025 Aug 20;13(8):2029. doi: 10.3390/biomedicines13082029.
7
An Overview of the Role of Medicinal Plants in Parkinson's Disease: A Semi-Systematic Review.药用植物在帕金森病中的作用概述:一项半系统综述
Biomedicines. 2025 Aug 18;13(8):2008. doi: 10.3390/biomedicines13082008.
8
Gut-brain nexus: Mapping multimodal links to neurodegeneration at biobank scale.肠-脑轴:在生物样本库规模上绘制与神经退行性变的多模态联系
Sci Adv. 2025 Aug 29;11(35):eadu2937. doi: 10.1126/sciadv.adu2937. Epub 2025 Aug 27.
9
Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review.海参衍生生物活性物质在预防和管理脑相关疾病中的治疗潜力:综述
Mar Drugs. 2025 Jul 30;23(8):310. doi: 10.3390/md23080310.
10
Treatment for Parkinson Disease: A Systematic Review of Clinical Trials.帕金森病的治疗:临床试验的系统评价
Parkinsons Dis. 2025 Aug 18;2025:1319419. doi: 10.1155/padi/1319419. eCollection 2025.
Front Neurosci. 2019 Mar 29;13:277. doi: 10.3389/fnins.2019.00277. eCollection 2019.
4
Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.靶向帕金森病中的α-突触核蛋白:开发疾病修饰治疗方法的进展。
Drugs. 2019 Jun;79(8):797-810. doi: 10.1007/s40265-019-01104-1.
5
Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein.锰促进α-突触核蛋白的聚集和朊病毒样细胞外泌体传递。
Sci Signal. 2019 Mar 12;12(572):eaau4543. doi: 10.1126/scisignal.aau4543.
6
Concordance for Parkinson's disease in twins: A 20-year update.双胞胎帕金森病的一致性:20 年的更新。
Ann Neurol. 2019 Apr;85(4):600-605. doi: 10.1002/ana.25441. Epub 2019 Mar 11.
7
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases.重新审视蛋白质聚集作为散发性帕金森病和阿尔茨海默病的致病因素。
Neurology. 2019 Feb 12;92(7):329-337. doi: 10.1212/WNL.0000000000006926.
8
The Emerging Evidence of the Parkinson Pandemic.帕金森病大流行的新证据。
J Parkinsons Dis. 2018;8(s1):S3-S8. doi: 10.3233/JPD-181474.
9
Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis.触发因素、促进因素和加重因素:重新定义帕金森病的发病机制。
Trends Neurosci. 2019 Jan;42(1):4-13. doi: 10.1016/j.tins.2018.09.007. Epub 2018 Oct 17.
10
Prevalence of Parkinson's disease across North America.北美帕金森病的患病率。
NPJ Parkinsons Dis. 2018 Jul 10;4:21. doi: 10.1038/s41531-018-0058-0. eCollection 2018.